GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

GenSight Biologics launches a capital increase of approximately €20 million

GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit

GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Academy of Neurology

GenSight Biologics to Present Data on GS010 at the 43rd Annual Meeting of NANOS

GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy